Inhibition of the Rho/ROCK pathway enhances the efficacy of cisplatin through the blockage of hypoxia-inducible factor-1alpha in human ovarian cancer cells

Cancer Biology and Therapy

Volumn 13, Issue 1, 2012, Pages 25-33

  Ohta, Tsuyoshi ^a   Takahashi, Toshifumi ^a   Shibuya, Tae ^a   Amita, Mitsuyoshi ^a   Henmi, Noriko ^a   Takahashi, Kazuhiro ^a   Kurachi, Hirohisa ^a  

^a YAMAGATA UNIVERSITY   (Japan)

Author keywords

Cisplatin; Fasudil; HIF 1; Ovarian cancer; Rho; ROCK1; ROCK2

Indexed keywords

4 (1 AMINOETHYL) N (4 PYRIDYL)CYCLOHEXANECARBOXAMIDE; CISPLATIN; FASUDIL; HYPOXIA INDUCIBLE FACTOR 1ALPHA; PROTEIN KINASE; PROTEIN ROCK1; PROTEIN ROCK2; RHOA GUANINE NUCLEOTIDE BINDING PROTEIN; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; 1 (5 ISOQUINOLINESULFONYL) 2 METHYLPIPERAZINE; DRUG DERIVATIVE; PROTEIN KINASE INHIBITOR; RHO KINASE; RHOA PROTEIN, HUMAN; ROCK1 PROTEIN, HUMAN; ROCK2 PROTEIN, HUMAN;

APOPTOSIS; ARTICLE; CANCER CELL; CANCER INHIBITION; CELL PROLIFERATION; CELL SURVIVAL; CELL VIABILITY; CYTOTOXICITY; DRUG EFFECT; DRUG EFFICACY; DRUG POTENTIATION; ENZYME INHIBITION; HUMAN; OVARY CANCER; PROTEIN EXPRESSION; DRUG ANTAGONISM; ENZYMOLOGY; FEMALE; GENE SILENCING; GENETICS; METABOLISM; OVARY TUMOR; TUMOR CELL LINE;

1-(5-ISOQUINOLINESULFONYL)-2-METHYLPIPERAZINE; CELL LINE, TUMOR; CISPLATIN; DRUG SYNERGISM; FEMALE; GENE KNOCKDOWN TECHNIQUES; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; OVARIAN NEOPLASMS; PROTEIN KINASE INHIBITORS; RHO-ASSOCIATED KINASES; RHOA GTP-BINDING PROTEIN;

EID: 84863080020     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.13.1.18440     Document Type: Article

References (35)

1. McGuire WP, Hoskins WJ, Brady MF, Kucera PR, Partridge EE, Look KY, et al. Cyclophosphamide and cisplatin versus paclitaxel and cisplatin: a phase III randomized trial in patients with suboptimal stage III/IV ovarian cancer (from the Gynecologic Oncology Group). Semin Oncol 1996; 23(suppl 12):40-7; PMID:8941409
2. Vasey PA, Atkinson R, Coleman R, Crawford M, Cruickshank M, Eggleton P, et al. Docetaxel-carboplatin as first line che motherapy for epithelial ovarian cancer. Br J Cancer 2001; 84:170-8; PMID:11161372; http://dx.doi.org/10.1054/ bjoc.2000.1572
3. Ducton CJ. New options for the treatment of advanced ovarian cancer. Semin Oncol 1997; 24(Suppl 5):2-11.
4. Dizon DS, Hensley ML, Poynor EA, Sabbatini P, Aghajanian C, Hummer A, et al. Retrospective analysis of carboplatin and paclitaxel as initial second-line therapy for recurrent epithelial ovarian carcinoma: application toward a dynamic disease state model of ovarian cancer. J Clin Oncol 2002; 20:1238-47; PMID:11870166; http://dx.doi.org/10.1200/JCO.20.5.1238
5. Chon HS, Hu W, Kavanagh JJ. Targeted therapies in gynecologic cancers. Curr Cancer Drug Targets 2006; 6:333-63; PMID:16848724; http://dx.doi.org/10. 2174/ 156800906777441799
6. Maxwell PH, Wiesener MS, Chang GW, Clifford SC, Vaux EC, Cockman ME, et al. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 1999; 399:271-5; PMID:10353251; http://dx.doi.org/10.1038/20459
7. Brown JM, Giaccia AJ. The unique physiology of solid tumors: opportunities (and problems) for cancer therapy. Cancer Res 1998; 58:1408-16; PMID:9537241
8. Osada R, Horiuchi A, Kikuchi N, Yoshida J, Hayashi A, Ota M, et al. Expression of hypoxia-inducible factor 1alpha, hypoxia-inducible factor 2alpha, and von Hippel-Lindau protein in epithelial ovarian neoplasms and allelic loss of von Hippel-Lindau gene: nuclear expression of hypoxia-inducible factor 1alpha is an independent prognostic factor in ovarian carcinoma. Hum Pathol 2007; 38:1310-20; PMID:17555795; http://dx.doi.org/10.1016/j.humpath.2007.02.010
9. Birner P, Schindl M, Obermair A, Breitenecker G, Oberhuber G. Expression of hypoxia-inducible factor 1alpha in epithelial ovarian tumors: its impact on prognosis and on response to chemotherapy. Clin Cancer Res 2001; 7:1661-8; PMID:11410504
10. Olson MF. Application for ROCK kinase inhibition. Curr Opin Cell Biol 2008; 20:242-8; PMID:18282695; http://dx.doi.org/10.1016/j.ceb.2008.01.002
11. Takata K, Morishige K, Takahashi T, Hashimoto K, Tsutsumi S, Yin L, et al. Fasudil-induced hypoxiainducible factor-1alpha degradation disrupts a hypoxiadriven vascular endothelial growth factor autocrine mechanism in endothelial cells. Mol Cancer Ther 2008; 7:1551-61; PMID:18566226; http://dx.doi.org/10. 1158/1535-7163.MCT-07-0428
12. Riento K, Ridley AJ. Rocks: multifunctional kinases in cell behavior. Nat Rev Mol Cell Biol 2003; 4:446-56; PMID:12778124; http://dx.doi.org/10.1038/ nrm1128
13. Scott RW, Olson MF. LIM kinase: function, regulation and association with human disease. J Mol Med 2007; 85:555-68; PMID:17294230; http://dx.doi.org/10. 1007/s00109-007-0165-6
14. Somlyo AP, Somlyo AV. Ca2+ sensitivity of smooth muscle and nonmuscle myosin II: modulated by G proteins, kinases, and myosin phosphatase. Physiol Rev 2003; 83:1325-58; PMID:14506307
15. Zicha D, Dobbie IM, Holy MR, Monypenny J, Soong DY, Gray C, et al. Rapid actin transport during cell protrusion. Science 2003; 300:142-5; PMID:12677069; http://dx.doi.org/10.1126/science.1082026
16. Amano M, Fukata Y, Kaibuchi K. Regulation and functions of Rho-associated kinase. Exp Cell Res 2000; 261:44-51; PMID:11082274; http://dx.doi.org/10. 1006/excr.2000.5046
17. Redowicz MJ. Rho-associated kinase: involvement in the cytoskeleton regulation. Arch Biochem Biophys 1999; 364:122-4; PMID:10087173; http://dx.doi.org/ 10.1006/abbi.1999.1112
18. Xue F, Takahara T, Yata Y, Xia Q, Nonome K, Shinno E, et al. Blockade of Rho/Rho-associated coiled coil-forming kinase signaling can prevent progression of hepatocellular carcinoma in matrix metalloproteinase-dependent manner. Hepatol Res 2008; 38:810-7; PMID:18507693; http://dx.doi.org/10.1111/j.1872- 034X.2008.00333.x
19. Sawada K, Morishige K, Tahara M, Ikebuchi Y, Kawagishi R, Tasaka K, et al. Lysophosphatidic acid induces focal adhesion assembly through Rho/Rho-associated kinase pathway in human ovarian cancer cells. Gynecol Oncol 2002; 87:252-9; PMID:12468322; http://dx.doi.org/10.1006/gyno.2002.6831
20. Ying H, Sandara LB, Li WW, Alicke B, Xuan JA, Pagila R, et al. The Rho kinase inhibitor fasudil inhibits tumor progression in human and rat tumor models. Mol Cancer Ther 2006; 5:2158-64; PMID:16985048; http://dx.doi.org/10. 1158/1535-7163.MCT-05-0440
21. Tachibana E, Harada T, Shibuya M, Saito K, Takayasu M, Suzuki Y, et al. Intra-arterial infusion of fasudil hydrochloride for treating vasospasm following subarachnoid haemorrhage. Acta Neurochir (Wien) 1999; 141:13-9; PMID:10071681; http://dx.doi.org/10.1007/ s007010050260
22. Shibuya M, Hirai S, Seto M, Satoh S, Ohtomo E & Fasudil Ischemic Stroke Study Group. Effects of fasudil in acute ischemic stroke: results of a prospective placebo-controlled double-blind trial. J Neurol Sci 2005; 238:31-9; PMID:16005902; http://dx.doi.org/ 10.1016/j.jns.2005.06.003
23. Igishi T, Mikami M, Murakami K, Matsumoto S, Shigeoka Y, Nakanishi H, et al. Enhancement of cisplatin-induced cytotoxicity by ROCK inhibitor through suppression of focal adhesion kinase-independent mechanism in lung carcinoma cells. Int J Oncol 2003; 23:1079-85; PMID:12963988
24. Hamilton TC, Winker MA, Louie KG, Batist G, Behrens BC, Tsuruo T, et al. Augmentation of adriamycin, melphalan, and cisplatin cytotoxicity in drug-resistant and -sensitive human ovarian carcinoma cell lines by buthionine sulfoximine mediated glutathione depletion. Biochem Pharmacol 1985; 34:2583-6; PMID:4040369; http://dx.doi.org/10.1016/0006-2952(85)90551-9
25. Mabuchi S, Ohmichi M, Nishio Y, Hayasaka T, Kimura A, Ohta T, et al. Inhibition of NFkappaB increases the efficacy of cisplatin in invitro and in vivo ovarian cancer models. J Biol Chem 2004; 279:23477-85; PMID: 15026414; http://dx.doi.org/10.1074/jbc.M313709200
26. Yin L, Morishige K, Takahashi T, Hashimoto K, Ogata S, Tsutsumi S, et al. Fasudil inhibits vascular endothelial growth factor-induced angiogenesis in vitro and in vivo. Mol Cancer Ther 2007; 6:1517-25; PMID:17513600; http://dx.doi.org/10.1158/1535-7163.MCT-06-0689
27. Kothakota S, Azuma T, Reinhard C, Kippel A, Tang J, Chu K, et al. Caspase-3-generated fragment of gelsolin: effector of morphological change in apoptosis. Science 1997; 278:294-8; PMID:9323209; http://dx.doi.org/ 10.1126/science.278.5336.294
28. Duyndam MC, Berkel MPA, Dorsman JC, Rockx DA, Pinedo HM, Boven E. Cisplatin and doxorubicin repress Vascular Endothelial Growth Factor expression and differentially down-regulate Hypoxia-inducible Factor I activity in human ovarian cancer cells. Biochem Pharmacol 2007; 74:191-201; PMID:17498666; http://dx.doi.org/10.1016/j.bcp.2007.04.003
29. Lowery DM, Clauser KR, Hjerrild M, Lim D, Alexander J, Kishi K, et al. Proteomic screen defines the Polo-box domain interactome and identifies Rock2 as a Plk1 substrate. EMBO J 2007; 26:2262-73; PMID: 17446864; http://dx.doi.org/ 10.1038/sj.emboj.7601683
30. Shibata R, Kai H, Seki Y, Kusaba K, Takemiya K, Koga M, et al. Rho-kinase inhibition reduces neointima formation after vascular injury by enhancing Bax expression and apoptosis. J Cardiovasc Pharmacol 2003; 42(Suppl 1):S43-7; PMID:14871028; http:// dx.doi.org/10.1097/00005344-200312001-00011
31. Moore M, Marroquin BA, Gugliotta W, Tse R, White SR. Rho kinase inhibition initiates apoptosis in human airway epithelial cells. Am J Respir Cell Mol Biol 2004; 30:379-87; PMID:12933355; http://dx.doi.org/10. 1165/rcmb.2003-0019OC
32. Minet E, Michel G, Remacle J, Michiels C. Role of HIF-1 as a transcription factor involved in embryonic development, cancer progression and apoptosis. [review]. Int J Mol Med 2000; 5:253-9; PMID: 10677565
33. Comerford KM, Wallance TJ, Karhausen J, Louis NA, Montalto MC, Colgan SP. Hypoxia-inducible Factor- 1-dependent regulation of multidrug resistance (MDR1) gene. Cancer Res 2002; 62:3387-94; PMID: 12067980
34. Fukuda R, Hirota K, Fan F, Jung YD, Ellis LM, Semenza GL. Insulin-like growth factor 1 induces hypoxia-inducible factor 1-mediated vascular endothelial growth factor expression, which is dependent on MAP kinase and phosphatidylinositol 3-kinase signaling in colon cancer cells. J Biol Chem 2002; 277: 38205-11; PMID:12149254; http://dx.doi.org/10.1074/ jbc.M203781200
35. Song Y, Wu J, Oyesanya RA, Lee Z, Mukherjee A, Fang X. Sp-1 and c-Myc mediate lysophosphatidic acid-induced expression of vascular endothelial growth factor in ovarian cancer cells via a hypoxia-inducible factor-1- independent mechanism. Clin Cancer Res 2009; 15: 492-501; PMID:19147754; http://dx.doi.org/10.1158/ 1078-0432.CCR-08-1945